Correlation Between Klaria Pharma and Kancera AB
Can any of the company-specific risk be diversified away by investing in both Klaria Pharma and Kancera AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Klaria Pharma and Kancera AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Klaria Pharma Holding and Kancera AB, you can compare the effects of market volatilities on Klaria Pharma and Kancera AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Klaria Pharma with a short position of Kancera AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Klaria Pharma and Kancera AB.
Diversification Opportunities for Klaria Pharma and Kancera AB
0.47 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Klaria and Kancera is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Klaria Pharma Holding and Kancera AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kancera AB and Klaria Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Klaria Pharma Holding are associated (or correlated) with Kancera AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kancera AB has no effect on the direction of Klaria Pharma i.e., Klaria Pharma and Kancera AB go up and down completely randomly.
Pair Corralation between Klaria Pharma and Kancera AB
Assuming the 90 days trading horizon Klaria Pharma Holding is expected to generate 0.73 times more return on investment than Kancera AB. However, Klaria Pharma Holding is 1.36 times less risky than Kancera AB. It trades about -0.08 of its potential returns per unit of risk. Kancera AB is currently generating about -0.12 per unit of risk. If you would invest 60.00 in Klaria Pharma Holding on September 1, 2024 and sell it today you would lose (15.00) from holding Klaria Pharma Holding or give up 25.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Klaria Pharma Holding vs. Kancera AB
Performance |
| Timeline |
| Klaria Pharma Holding |
| Kancera AB |
Klaria Pharma and Kancera AB Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Klaria Pharma and Kancera AB
The main advantage of trading using opposite Klaria Pharma and Kancera AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Klaria Pharma position performs unexpectedly, Kancera AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will offset losses from the drop in Kancera AB's long position.| Klaria Pharma vs. Kancera AB | Klaria Pharma vs. Cyxone AB | Klaria Pharma vs. Lidds AB | Klaria Pharma vs. Cantargia AB |
| Kancera AB vs. Combigene AB | Kancera AB vs. Cantargia AB | Kancera AB vs. Fingerprint Cards AB | Kancera AB vs. Spectrumone publ AB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |